Aurinia Pharmaceuticals Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Aurinia reported H1 2026 total revenue of $160.9M (up 21% YoY), with LUPKYNIS net product sales of $153.0M (up 21% YoY). Net income jumped 60% to $71.8M and diluted EPS grew 66% to $0.53. The company repurchased 5.0M shares for $74.9M and reiterates full-year 2026 revenue guidance of $315–$325M. R&D spending increased to $20.5M (up 56% YoY) as the company initiated the PRESERVE Phase 4 study combining LUPKYNIS with three biologic agents and advanced aritinercept into four indications.
Why this rating
Strong organic revenue and earnings growth (~16% relative to ~$1B market cap) with improved cash generation, but offset by rising R&D and competitive-phase pipeline risk.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.